Tianjin Zhong Xin Pharmaceutical Group says Jinhushen Biological Medical Science and Technology has completed its acquisition in its controlling shareholder, Tianjin Pharmaceutical Holdings (TPH) on

Jinhushen Bio completes 67% acquisition with Tianjin Pharma, S shares offer price revised

Tianjin Zhong Xin Pharmaceutical Group announced on Dec 20 that Jinhushen Biological Medical Science and Technology has acquired a 67% stake in its controlling shareholder, Tianjin Pharmaceutical

Jinhushen Biological Medical Science and Technology to acquire 67% stake in Tianjin Zhong Xin’s controlling shareholder for undisclosed sum

Tianjin Pharmaceutical Holdings (TPH)

ESR-LOGOS REIT reports 2HFY2022 DPU of 1.54 cents, up by 7.5% y-o-y

Analysts see 'resilient' results for MLT's 3QFY2023 although Citi sees 'negative' share impact on forex weakness

How LREIT became the first net-zero S-REIT

Pushing for a passwordless future

Maximising the ROI of low-code development

Chinese search giant Baidu to launch ChatGPT-style bot

US stocks are poised to hit new lows this year, survey of investors shows

Malaysia PM Anwar tells Goldman to pay up on 1MDB settlement

Anwar vows gradual debt reduction to ensure stability

Timekeepers for the new year

See the latest from Fendi, Chaumet and more

The art of Kappo

The green future of industrial sustainability

Future of finance: How DeFi could help traditional finance

China recalibrates its policies: What does that mean?

RHB Singapore offers exclusive 4.28% p.a. fixed deposit rate at refreshed Cecil branch

Grab receives a more bullish call from Aletheia Capital; takeover of GoTo reiterated

Capital World to sell most of its space at its Johor mall to Mustafa for RM368 mil

Phillip Securities keeps an eye on 'disinflation' and China reopening exposure in picking its 10 stocks

Mercatus divests 50% indirect stake in Nex for $652.5 mil